CK-102 / Fortress, Teva - LARVOL DELTA

Uncovering genetic and phenotypic diversity connections in Lachancea thermotolerans: impact on wine aromatics. (PubMed, Food Microbiol) - "All strains yielded less ethanol and more succinic acid than Saccharomyces cerevisiae strain SafOeno™ CKS102, and several consumed over 50% of initial malic acid...Interestingly, some also produced high levels of terpenes and aldehydes, which are underexplored in L. thermotolerans, suggesting further potential to enhance aroma complexity. These findings advance understanding of L. thermotolerans strain diversity and highlight untapped potential for selecting strains with desirable traits for tailored wine production."

Journal

The combination therapy of isomucronulatol 7-O-beta-glucoside (IMG) and CEP-9722 targeting ferroptosis-related biomarkers in non-small cell lung cancer (NSCLC). (PubMed, BMC Pulm Med) - "We identified an effective ferroptosis-related prognostic model based on single-cell sequencing. The potential prediction model is devoted to exploring clinical therapeutic targets for NSCLC."

Biomarker • Combination therapy • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP1-2 inhibitor) as single agent and in combination with temozolomide in patients with advanced solid tumors (NCT00920595) (ASCO 2012) - Presentation time: Mon, Jun 4, 8:00 AM - 12:00 PM; Anticipated presentation at ASCO 2012

Anticipated P1 data presentation • Oncology

Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP1-2 inhibitor) as single agent and in combination with temozolomide in patients with advanced solid tumors (NCT00920595) (ASCO 2012) - Presentation time: Monday June 4, 8:00 AM to 12:00 PM; P1, N=26; The MTD of CEP-9722 in combination with TMZ (150 mg/m2) was reached at 1000 mg/day; Pharmacodynamic analysis demonstrated PARP inhibition at all doses

P1 data • Oncology

Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. (PubMed, Curr Treat Options Oncol) - "Olaparib, rucaparib, and niraparib all have indications for maintenance therapy in recurrent platinum-sensitive ovarian cancer after response to platinum-based therapy. Other newer agents such as talazoparib, veliparib, 2X-121, and CEP-9722 are in earlier stages of development. As more FDA-approved indications for PARP inhibitor therapy in ovarian cancer become available, we anticipate the decision of which PARP inhibitor to use will become increasingly complex."

Biomarker • BRCA Biomarker • Clinical • Journal • PARP Biomarker • Review